THE BioMed Co., Ltd. (KOSDAQ:214610)

Market Cap	30.38B
Revenue (ttm)	4.59B
Net Income (ttm)	-27.71B
Shares Out	5.15M
EPS (ttm)	-6,082.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,244,788
Average Volume	242,721
Open	6,590.00
Previous Close	5,420.00
Day's Range	6,040.00 - 7,040.00
52-Week Range	4,360.00 - 33,100.00
Beta	0.51
RSI	57.31
Earnings Date	Aug 14, 2025

About THE BioMed

THE BioMed Co., Ltd. provides point-of-care-testing diagnostic systems based on Lab-on-a-Chip technology. The company offers molecular diagnostics devices comprising Veri-Q PREP M16 (G2-16TU) system, a device that include membrane to extract nucleic acid using tube; VERI-Q PCR 316, a device to get the result in a short time using plastic chip; VERI-Q PCR 204 (G2-4), a device to deliver the real-time PCR system; PCR and sample prep kits; Veri-Q PCR 316 PB products; and LabChip, sample tube, and pre-filtering column products. It also provides bio...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 2009
• Employees: 50
• Stock Exchange: KOSDAQ
• Ticker Symbol: 214610

Financial Performance

In 2024, THE BioMed's revenue was 4.64 billion, a decrease of -13.55% compared to the previous year's 5.37 billion. Losses were -30.85 billion, 19.7% more than in 2023.